ILLUMINA, INC. — Form 10-Q
Filed October 30, 2026 · analyzed by the Periodic Agent
10-Q
▼ Likely negative
significance 28/100
What the filing says
On July 24, 2026, Illumina paid Standard BioTools Inc. $30,041,683.63 to fully terminate all contingent obligations arising from their June 2025 stock purchase agreement. This single payment eliminates: (1) any 2026 earnout payment; (2) 2% royalty on SOMAmer-based NGS library kits; (3) 5% royalty on Single SOMAmers; and (4) the license agreement for Single SOMAmers and related products. All royalty agreements and the license agreement are terminated effective upon receipt of payment.
Why this rating
One-time $30M cash outflow (~0.3% of $9.2B market cap) to extinguish future contingent liabilities. Eliminates ongoing royalty drag but reflects prior acquisition complications; modest absolute cost relative to company size.
See more from October 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.